Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi SyndromePRNewsWire · 2 days ago
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's DiseasePRNewsWire · 4 days ago
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal HyperplasiaPRNewsWire · Oct 16, 2026
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-TermZacks Investment Research · Oct 14, 2026
NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?Zacks Investment Research · Oct 13, 2026
Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermZacks Investment Research · Oct 13, 2026Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $1.85 | $2.85 | Beat |
| May 5, 2026 | $1.22 | $1.91 | Beat |
| Feb 11, 2026 | $1.80 | $1.88 | Beat |
| Oct 28, 2025 | $1.58 | $2.04 | Beat |
| Jul 30, 2025 | $0.98 | $1.06 | Beat |
| May 5, 2025 | $0.54 | $0.08 | Miss |